TradingView report covering Lifeward Ltd. (LFWD) market action, institutional positioning, and fundamental catalysts.
Why LFWD Stock advanced +1.82% Today — RQD Quant Desk Flash
Lifeward Ltd. (LFWD) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is LFWD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Lifeward Ltd. (NASDAQ: LFWD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $6.06 (+1.82% 1D, market cap $16.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, LFWD ranks #736 in composite RQD confidence.
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does LFWD compare to HSCS and CUPR in the Health Care sector?
▼
Within the Health Care sector (Industrial Specialties), LFWD carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, HSCS (HeartSciences Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $16.0M) and CUPR (Cuprina Holdings (Cayman) Limited (Class A)) posts a E grade (21/100 RQD, P/E N/A, ROIC -35.0%, cap $13.5M). Among the 5-stock peer group, MLSS leads on earnings multiple (5.0x) while LFWD leads on capital efficiency (-35.0% ROIC).
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for LFWD?
▼
Per LFWD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001607962), Lifeward Ltd. generated $1.4M in revenue (-17.6% YoY), -$19.9M in net income, and -$16.8M in free cash flow against $22.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 602% Gross Margin
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
⚔️ Adversarial Opposing Case: What Could Spark a LFWD Turnaround Squeeze
While LFWD currently carries a cautious 32/100 (E) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.61) and Max Pain ($6.36) forces dealer call-delta covering toward $10.09.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Why LFWD Stock advanced +1.82% Today — RQD Quant Desk Flash
Lifeward Ltd. (LFWD) advanced +1.82% to $6.06, trading at 35% of its 52-week range ($4.14 – $9.61). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 35% of its 52-week range ($4.14 – $9.61) with RSI-14 at 45.1 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±9.9% around $6.06 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 602% gross margin and $0 annual free cash flow.
Yahoo Finance UK report covering Lifeward Ltd. (LFWD) market action, institutional positioning, and fundamental catalysts.
www.marketscreener.com report covering Lifeward Ltd. (LFWD) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Lifeward Ltd. (LFWD) market action, institutional positioning, and fundamental catalysts.
Investing.com Australia report covering Lifeward Ltd. (LFWD) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Lifeward Ltd. (LFWD) market action, institutional positioning, and fundamental catalysts.
www.dars.gov.et report covering Lifeward Ltd. (LFWD) market action, institutional positioning, and fundamental catalysts.
Publication of an independent, investigator-initiated peer-reviewed study which provides long-term real-world evidence on the safety, utilization and user experience of the ReWalk® Personal Exoskeleton in individuals
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LFWD)
- ✓Walkthrough of LFWD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
LFWD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -17.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on LFWD today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for LFWD. Explore sector supply chains on /butterfly.
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LFWD)
1. Head-to-Head Health Care Peer Comparison (LFWD vs. HSCS, CUPR, CLGN, MLSS)
Industry: Industrial Specialties (55 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Lifeward Ltd. (LFWD) ranks #736 by composite RQD confidence (32/100, grade E) and #840 by equity capitalization ($16.9M). Within this direct 5-issuer industry benchmark cohort, MLSS leads on earnings valuation at 5.0x trailing P/E, while LFWD leads on capital efficiency and profitability with -35.0% ROIC and 96.0% gross margin. CLGN currently holds the highest overall quantitative score in the immediate peer group at 41/100 (D-) compared with LFWD at 32/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| LFWD
ACTIVE
Lifeward Ltd. | E | 32/100 | — | 96.0% | -35.0% | +1.82% | $16.9M | Benchmark Subject |
| HSCS HeartSciences Inc. | D- | 38/100 | — | 59.1% | -35.0% | -9.67% | $16.0M | /hscs-vs-lfwd → |
| CUPR Cuprina Holdings (Cayman) Limited (Class A) | E | 21/100 | — | -1.3% | -35.0% | +3.96% | $13.5M | /cupr-vs-lfwd → |
| CLGN CollPlant Biotechnologies Ltd | D- | 41/100 | — | 64.8% | -35.0% | -1.33% | $11.9M | /clgn-vs-lfwd → |
| MLSS Milestone Scientific Inc. | D- | 40/100 | 5.0x | 71.4% | -35.0% | +5.88% | $27.6M | /mlss-vs-lfwd → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001607962 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Lifeward Ltd. (LFWD) reported GAAP revenue of $1.4M (-17.6% vs. FY2024 revenue of $1.7M , and +221.8% cumulative change since FY2023) , GAAP net income of -$19.9M, operating cash flow of -$16.8M, and free cash flow of -$16.8M (+22.5% YoY). On the balance sheet, LFWD closed FY2025 with $22.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $1.4M | -$19.9M | -$16.8M | -$16.8M | $22.9M | — |
| FY2024 (FY) | 2024-12-31 | $1.7M | -$28.9M | -$21.7M | -$21.7M | $30.5M | — |
| FY2023 (FY) | 2023-12-31 | $435.0K | -$22.1M | -$20.7M | -$20.7M | — | — |
3. LFWD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs LFWD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Lifeward Ltd. (NASDAQ: LFWD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $6.06 (+1.82% 1D, market cap $16.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, LFWD ranks #736 in composite RQD confidence.
How does LFWD compare to HSCS and CUPR in the Health Care sector?
Within the Health Care sector (Industrial Specialties), LFWD carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, HSCS (HeartSciences Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $16.0M) and CUPR (Cuprina Holdings (Cayman) Limited (Class A)) posts a E grade (21/100 RQD, P/E N/A, ROIC -35.0%, cap $13.5M). Among the 5-stock peer group, MLSS leads on earnings multiple (5.0x) while LFWD leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for LFWD?
Per LFWD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001607962), Lifeward Ltd. generated $1.4M in revenue (-17.6% YoY), -$19.9M in net income, and -$16.8M in free cash flow against $22.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is LFWD trading relative to its 50-day, 200-day, and 52-week technical levels?
LFWD last traded at $6.06 (+1.82% on volume of 94,506 shares), positioning the stock -8.32% below its 50-day simple moving average ($6.61) and -12.68% below its 200-day simple moving average ($6.94). Across its 52-week range of $4.14 to $9.61, LFWD sits at the 35.1% percentile with a 14-day RSI of 45.1 (NEUTRAL RANGE) and an implied next-earnings move of ±9.9% ($5.46 to $6.66).
LFWD — Lifeward Ltd.: What the Facts Mean to a Prospective Investor
1. Roarable Rating Brief: What This Means to a Prospective Investor
Lifeward Ltd. (LFWD) earns a live Roarable RQD composite score of 32/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $6.06 (+1.82% 1D, market capitalization $16.9M).
- Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 96.0%, operating margin of -60.0%, and free cash flow yield of —.
- Whale 13F & Options Flow (5/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (6/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 4/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Lifeward Ltd. Is a NASDAQ-listed issuer in the Health Care sector, within the Industrial Specialties industry,. The source does not describe its products, customers, or revenue model in detail. The SEC financials show reported revenue of $1.4M in FY 2025, $1.7M in FY 2024, and $0.4M in FY 2023. The news wire references the ReWalk® Personal Exoskeleton, indicating the company's product focus.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Lifeward Ltd. (LFWD) reported $1.4M in annual revenue (up from $1.7M in FY2024, -17.6% YoY) and -$19.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($435.0K revenue, -$22.1M net income) through FY2025, LFWD scaled operating cash flow to -$16.8M and free cash flow to -$16.8M, backed by $22.9M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (E • RQD 32/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 5/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $4.14 – $9.61 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the source data. A prospective investor should watch for finance-leadership continuity given the interim arrangement referenced in the news wire, and for cash-runway implications given the decline in reported cash.
- Key Question #1: Can LFWD sustain or expand its -60.0% operating margin and -35.0% ROIC against Industrial Specialties peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $1.4M and free cash flow of -$16.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is LFWD's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
LFWD Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Lifeward Ltd. (LFWD) • Click "Debate This Headline" to argue it in the Roar Pit below
TradingView report covering Lifeward Ltd. (LFWD) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering Lifeward Ltd. (LFWD) market action, institutional positioning, and fundamental catalysts.
www.marketscreener.com report covering Lifeward Ltd. (LFWD) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Lifeward Ltd. (LFWD) market action, institutional positioning, and fundamental catalysts.
Investing.com Australia report covering Lifeward Ltd. (LFWD) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Lifeward Ltd. (LFWD) market action, institutional positioning, and fundamental catalysts.
www.dars.gov.et report covering Lifeward Ltd. (LFWD) market action, institutional positioning, and fundamental catalysts.
Publication of an independent, investigator-initiated peer-reviewed study which provides long-term real-world evidence on the safety, utilization and user experience of the ReWalk® Personal Exoskeleton in individuals
LFWD Bull vs. Bear Conversation Board — What's Your Call at $6.06?
The forensic balance-sheet pillar is the strongest in the rating, at 10 of 20, supported by an Altman Z of 2.5 and Debt/Equity of 0.5.
The street is overcomplicating Lifeward Ltd. (LFWD). The forensic balance-sheet pillar is the strongest in the rating, at 10 of 20, supported by an Altman Z of 2.5 and Debt/Equity of 0.5.. With an RQD score of 32/100 (E) and Forensic Balance Sheet at 10/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $6.43.
@SiliconVal_Bull Agree on the RQD 32/100 quality, though with 1.0 beta I'm scaling in with half-size at $5.95 and keeping dry powder in case we test $5.53.
Reported operating and net losses with negative free cash flow in every period shown, and ROIC of -35%, point to a business that is not
Reported operating and net losses with negative free cash flow in every period shown, and ROIC of -35%, point to a business that is not self-funding.. Look at the math on LFWD: paying current EV/EBITDA multiples for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Industrial Specialties demand softens. I'd wait for a retest of $5.24 before getting long.